Jasper Therapeutics appointed Jeet Mahal as the new CEO and member of the Board, replacing Ronald Martell.
Thomas Wiggans is now the Executive Chairperson of Jasper.
Investor webinar scheduled on January 8, 2026, to present updated data from BEACON study in CSU and open-label extension studies.
Leadership Change
Jeet Mahal appointed as CEO, bringing over 30 years of experience in the life sciences industry.
Strategic Vision
Focus on transitioning briquilimab into Phase 2b study in CSU under Mahal's leadership.
Webinar Presentation
Upcoming investor webinar on January 8, 2026, to share updated data from clinical studies.
- Jeet Mahal's appointment signals a strategic shift towards advancing briquilimab development in mast cell driven diseases.
- Investor confidence may strengthen with experienced leadership driving the clinical growth phase.
Jasper Therapeutics is poised for growth under Jeet Mahal's leadership as they focus on developing briquilimab for chronic mast cell diseases.